Key features and details
- PE/Cy7® Mouse monoclonal [L243] to HLA-DR
- Suitable for: Flow Cyt
- Reacts with: Human
- Conjugation: PE/Cy7®. Ex: 496nm, Em: 774nm
- Isotype: IgG2a
Related conjugates and formulations
Product namePE/Cy7® Anti-HLA-DR antibody [L243]
See all HLA-DR primary antibodies
DescriptionPE/Cy7® Mouse monoclonal [L243] to HLA-DR
ConjugationPE/Cy7®. Ex: 496nm, Em: 774nm
Tested applicationsSuitable for: Flow Cytmore details
Species reactivityReacts with: Human
Tissue, cells or virus corresponding to Human HLA-DR. Human B lymphocytes.
- Flow Cyt: Human peripheral blood.
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Storage instructionsShipped at 4°C. Store at +4°C. Store In the Dark.
Storage bufferpH: 7.4
Preservative: 0.0975% Sodium azide
Concentration information loading...
Purification notesThe purified antibody is conjugated with tandem dye PE-Cy™7 under optimum conditions. The conjugate is purified by size-exclusion chromatography and adjusted for direct use. No reconstitution is necessary.
- Anti-HLA-DR antibody [L243] (ab136320)
- PerCP/Cy5.5® Anti-HLA-DR antibody [L243] (ab157330)
- FITC Anti-HLA-DR antibody [L243] (ab210298)
- Alexa Fluor® 647 Anti-HLA-DR antibody [L243] (ab239277)
- PE/Cy5® Anti-HLA-DR antibody [L243] (ab239296)
- APC/Cy7® Anti-HLA-DR antibody [L243] (ab239308)
- PE/DyLight™ 594 Anti-HLA-DR antibody [L243] (ab239320)
- redFluor™ 710 Anti-HLA-DR antibody [L243] (ab253079)
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab239318 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use 4µl for 106 cells.
(or 100 µl of whole blood)
Use 4µl for 106 cells.
(or 100 µl of whole blood)
FunctionBinds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form an heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal miroenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading.
Sequence similaritiesBelongs to the MHC class II family.
Contains 1 Ig-like C1-type (immunoglobulin-like) domain.
modificationsUbiquitinated by MARCH1 or MARCH8 at Lys-244 leading to down-regulation of MHC class II. When associated with ubiquitination of the beta subunit of HLA-DR: HLA-DRB4 'Lys-254', the down-regulation of MHC class II may be highly effective.
Cellular localizationCell membrane. Endoplasmic reticulum membrane. Golgi apparatus > trans-Golgi network membrane. Endosome membrane. Lysosome membrane. Late endosome membrane. The MHC class II complex transits through a number of intracellular compartments in the endocytic pathway until it reaches the cell membrane for antigen presentation.
- Information by UniProt
- DASS-397D15.1 antibody
- DR alpha chain antibody
- DR alpha chain precursor antibody
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab239318 has not yet been referenced specifically in any publications.